Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 4454-4460

  Song, Zhangjuan ^a,b   Deng, Yan ^a   Zhuang, Kangmin ^a   Li, Aimin ^a   Liu, Side ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal carcinomas; HER2 neu; Rabbit monoclonal antibody

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ANIMAL; BIOSYNTHESIS; COLORECTAL NEOPLASMS; DIAGNOSTIC USE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROCEDURES; RABBIT; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RABBITS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906231326     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
3. Gutierrez C and Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 2011; 135: 55-62.
4. Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD and Sinicrope FA. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 2004; 108: 540-548.
5. Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani F, Eustace PW and Tobbia I. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009; 9: 1.
6. Kim JY, Lim SJ and Park K. Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarrays. Appl Immunohistochem Mol Morphol 2004; 12: 67-70.
7. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D and Economopoulos T. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J 2006; 12: 229-236.
8. Li Q, Wang D, Li J and Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer 2011; 11: 277.
9. Nathanson DR, Culliford ATt, Shia J, Chen B, D'Alessio M, Zeng ZS, Nash GM, Gerald W, Barany F and Paty PB. HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 2003; 105: 796-802.
10. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y and Dobashi Y. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004; 17: 895-904.
11. Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G and Izbicki JR. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol 2010; 41: 1577-1585.
12. Spieker-Polet H, Sethupathi P, Yam PC and Knight KL. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc Natl Acad Sci U S A 1995; 92: 9348-9352.
13. Rossi S, Laurino L, Furlanetto A, Chinellato S, Orvieto E, Canal F, Facchetti F, Dei Tos AP. Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol 2005; 124: 295-302.
14. Manion E, Hornick JL, Lester SC and Brock JE. A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. Am J Clin Pathol 2011; 135: 845-851.
15. Hamilton SRB, Boffetta P, et al. WHO Clasification of Tumours of the Digestive System. Lyon: IARC; 2010.
16. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G and Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
17. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J and Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
18. Verbanac KM, Gross U, Rebellato LM and Thomas JM. Generation of rabbit anti-lymphocyte monoclonal antibodies. Transplant Proc 1993; 25: 837-838.
19. Blok EJ, Kuppen PJ, van Leeuwen JE and Sier CF. Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. Clin Med Insights Oncol 2013; 7: 41-51.
20. Nunes CB, Rocha RM, Reis-Filho JS, Lambros MB, Rocha GF, Sanches FS, Oliveira FN and Gobbi H. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol 2008; 61: 934-938.